Article

Minimal Residual Disease in Oncology: From Cure to Longitudinal Patient Management

2026-03-02

Abstract excerpt

Minimal residual disease (MRD) refers to the persistence of low-level malignant cells or tumor-derived nucleic acids that remain after curative-intent therapy and are undetectable by conventional diagnostic methods. In oncology, MRD has emerged as a powerful biomarker with well-established prognostic value in hematologic malignancies and rapidly expanding relevance in solid tumors. Advances in sensitive detection...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2988fc45-c60c-5da7-9599-dad9ec46c794
DOI: 10.20944/preprints202603.0155.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Minimal Residual Disease in Oncology: From Cure to Longitudinal Patient ManagementDOI 10.20944/preprints202603.0155.v1Read

Minimal Residual Disease Monitoring with Next-Generation Sequencing Methodologies in Hematological MalignanciesSemantic proximity Read

Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNASemantic proximity Read

Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual DiseaseSemantic proximity Read

Prognostic and Therapeutic Implications of Measurable Residual Disease Detection Across Hematologic Malignancies: Clinical Impact on Relapse Prediction and Survival OutcomesSemantic proximity Read

Minimal Residual Disease Detection in Acute Lymphoblastic LeukemiaSemantic proximity Read

Minimal Residual Disease as a Biological Trait: Rethinking Disease Persistence in Hematologic Malignancies.Semantic proximity Read

Advances in the assessment of minimal residual disease in mantle cell lymphomaSemantic proximity Read

High-throughput sequencing for noninvasive disease detection in hematologic malignanciesSemantic proximity Read

Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies?Semantic proximity Read

Molecular Minimal Residual Disease Monitoring in Acute Myeloid Leukemia: Challenges and Future Directions.Semantic proximity Read

An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemiaSemantic proximity Read

Analytical Validation of a Circulating Tumor DNA Assay using PhasED-Seq Technology for Detecting Residual Disease in B-Cell MalignanciesSemantic proximity Read